The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2019 | Preclinical results of a CD200-directed antibody in AML
CD200 is an important immune checkpoint protein, whose expression is associated with poor prognosis. Here, Namrata Rastogi, PhD, Cardiff University, Cardiff, UK, discusses the promising preclinical investigation of a CD200 blocking antibody in acute myeloid leukemia (AML) and exciting plans for a Phase I trial. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.
